Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for InSilico Medicine Cayman TopCo's Dividend Yield % or its related term are showing as below:
ISLMF's Dividend Yield % is not ranked *
in the Software industry.
Industry Median: 2.16 * Ranked among companies with meaningful Dividend Yield % only.
InSilico Medicine Cayman TopCo (OTCPK:ISLMF) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo Dividend Yield % Chart
For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InSilico Medicine Cayman TopCo Dividend Yield % vs Software Industry
For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where InSilico Medicine Cayman TopCo's Dividend Yield % falls into.
InSilico Medicine Cayman TopCo (ISLMF) has a Dividend Yield % of 0.00% as of Aug. 27, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on InSilico Medicine Cayman TopCo and its competitors. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #999999 out of 995 companies in the Software industry.
Is InSilico Medicine Cayman TopCo's Dividend Yield % too high?
InSilico Medicine Cayman TopCo's current Dividend Yield % is 0.00%. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #999999 out of 995 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's Dividend Yield % compare to ?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #999999 out of 995 companies for Dividend Yield %. This places InSilico Medicine Cayman TopCo in the lower half of its industry. The industry median Dividend Yield % is 2.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Software company?
The median Dividend Yield % among Software companies is 2.16, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on InSilico Medicine Cayman TopCo and its competitors. For the Software industry, the median Dividend Yield % is 2.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InSilico Medicine Cayman TopCo's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (ISLMF) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. InSilico Medicine Cayman TopCo's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (ISLMF), the current Dividend Yield % is 0.00% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
13GF Score
Get the complete analysis for ISLMF
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISLMF has been successfully added to your 
